Spinning for sight: exercise trial targets vision loss in veterans
NCT ID NCT05932069
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests whether a 6-month online stationary cycling program can improve vision, physical function, and thinking skills in veterans aged 65-89 with intermediate age-related macular degeneration (AMD). Researchers will measure contrast sensitivity, night vision, and visual acuity. The goal is to find a safe, accessible way to reduce the burden of AMD, which currently has no cure.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- stationary cycling (spinning)
- What this could lead to
- If it works, this could offer a simple, drug-free way to slow vision loss and improve daily function in people with AMD.
- What could go wrong
- This is a small, early-stage study with only 70 participants. Exercise may not improve vision significantly, and results may not apply to all AMD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlanta VA Medical and Rehab Center, Decatur, GA
RECRUITINGDecatur, Georgia, 30033-4004, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home eye scans personalize wet AMD treatment?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study
- Cheaper eye drug could save millions in AMD treatment costs